Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197827 · ClinicalTrials.gov registry record · Phase 1
A Study of YL242 in Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 424
- Enrollment target
- 15
- Study locations
NCT07197827: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..
NCT07197827 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 424 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (122% higher). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197827, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 424 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Primary Outcome
Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- DRUG YL242
- DRUG YL242; Pembrolizumab
- DRUG YL242; 5-FU; LV
- DRUG YL242; Pembrolizumab; 5-FU
Study Locations (15)
Victoria
- AUS-102 - Darlinghurst
- AUS-104 - Fitzroy
- AUS-103 - Heidelberg
Texas
- US-203 - Houston
- US-207 - San Antonio
Connecticut
- US-201 - New Haven
Florida
- US-202 - Sarasota
Massachusetts
- US-204 - Boston
Michigan
- US-206 - Grand Rapids
Tennessee
- US-205 - Nashville
New South Wales
- AUS-101 - Liverpool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
What NCT07197827 shows while recruiting
NCT07197827 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (122% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which YL242 is the first listed.
NCT07197827 lists 15 locations in 12 states (Victoria, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07197827 about?
NCT07197827 is a clinical study titled "A Study of YL242 in Subjects With Advanced Solid Tumors". This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
What is the current status of trial NCT07197827?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 424 participants. The study started on 2025-09-22. Estimated completion is 2028-11.
What conditions does trial NCT07197827 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT07197827?
The interventions under investigation include: YL242 (DRUG), YL242; Pembrolizumab (DRUG), YL242; 5-FU; LV (DRUG), YL242; Pembrolizumab; 5-FU (DRUG).
Who is sponsoring clinical trial NCT07197827?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197827 being conducted?
This trial has 15 study locations across Connecticut, Florida, Massachusetts, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07197827's enrollment target sits among peer trials
424 17th of 189 higher than 173 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI